.jetcityimage/iStock Content using Getty Images Morgan Stanley has actually opted for Eli Lilly (NYSE: LLY) as its own leading biopharma pick for 2025 and also rated an additional nine names in the area as over weight. The assets banking company pointed out in a keep in mind that it continues to feel “diabesity is set to come to be.